Published in Med Mycol on January 01, 2000
Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov (2009) 3.20
Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother (2002) 2.30
Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot Cell (2008) 1.73
Uptake of Aspergillus fumigatus Conidia by phagocytic and nonphagocytic cells in vitro: quantitation using strains expressing green fluorescent protein. Infect Immun (2002) 1.67
Sequential exposure to carbon nanotubes and bacteria enhances pulmonary inflammation and infectivity. Am J Respir Cell Mol Biol (2007) 1.60
Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis. Antimicrob Agents Chemother (2006) 1.47
Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob Agents Chemother (2003) 1.36
Critical annotations to the use of azole antifungals for plant protection. Antimicrob Agents Chemother (2001) 1.26
Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol (2006) 1.22
Management of neonatal candidiasis. Neonatal Candidiasis Study Group. Pediatr Infect Dis J (1998) 1.19
Candida albicans sterol C-14 reductase, encoded by the ERG24 gene, as a potential antifungal target site. Antimicrob Agents Chemother (2002) 1.13
Antifungal activity of tamoxifen: in vitro and in vivo activities and mechanistic characterization. Antimicrob Agents Chemother (2009) 1.12
Ocular and systemic posaconazole(SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis. Br J Ophthalmol (2002) 1.07
Inhibition of fungal and bacterial plant pathogens in vitro and in planta with ultrashort cationic lipopeptides. Appl Environ Microbiol (2007) 1.01
Syntheses and biological activity studies of novel sterol analogs from nitroso Diels-Alder reactions of ergosterol. Org Lett (2009) 0.97
Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis. Antimicrob Agents Chemother (2002) 0.94
Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob Agents Chemother (2004) 0.94
Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob Agents Chemother (2002) 0.91
Comparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus spp. Antimicrob Agents Chemother (2003) 0.88
Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother (2004) 0.87
Pharmacokinetics of antifungal agents in children. Early Hum Dev (2011) 0.85
2-Amino-nonyl-6-methoxyl-tetralin muriate inhibits sterol C-14 reductase in the ergosterol biosynthetic pathway. Acta Pharmacol Sin (2009) 0.81
Nitroso Diels-Alder (NDA) reaction as an efficient tool for the functionalization of diene-containing natural products. Org Biomol Chem (2014) 0.80
Safety and tolerability of voriconazole in patients with baseline renal insufficiency and candidemia. Antimicrob Agents Chemother (2012) 0.79
Pediatric antifungal agents. Curr Opin Infect Dis (2009) 0.79
Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole. Curr Drug Metab (2013) 0.79
Regulation of expression, activity and localization of fungal chitin synthases. Med Mycol (2011) 0.78
A review of clinical experience with newer antifungals in children. J Pediatr Pharmacol Ther (2008) 0.76
Fungal cell wall septation and cytokinesis are inhibited by bleomycins. Antimicrob Agents Chemother (2003) 0.76
Ruta montana L. leaf essential oil and extracts: characterization of bioactive compounds and suppression of crown gall disease. EXCLI J (2015) 0.75
RNA Sequencing Reveals that Endoplasmic Reticulum Stress and Disruption of Membrane Integrity Underlie Dimethyl Trisulfide Toxicity against Fusarium oxysporum f. sp. cubense Tropical Race 4. Front Microbiol (2017) 0.75
Antifungal therapy in children: an update. Eur J Pediatr (2012) 0.75
Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob Agents Chemother (1990) 8.42
Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother (2003) 7.09
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol (1997) 5.64
A simple system for the presumptive identification of Candida albicans and differentiation of strains within the species. Sabouraudia (1980) 5.47
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect (2012) 4.56
Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev (2001) 4.49
Use of specialised isolation media for recognition and identification of Candida dubliniensis isolates from HIV-infected patients. Eur J Clin Microbiol Infect Dis (1997) 3.86
Molecular mechanisms of drug resistance in fungi. Trends Microbiol (1994) 3.55
NRG1 represses yeast-hypha morphogenesis and hypha-specific gene expression in Candida albicans. EMBO J (2001) 3.48
Quality control guidelines for National Committee for Clinical Laboratory Standards--recommended broth macrodilution testing of ketoconazole and itraconazole. J Clin Microbiol (1996) 3.42
Characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother (1992) 3.23
Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology (1999) 3.19
Laboratory evaluation of antifungal agents: a comparative study of five imidazole derivatives of clinical importance. J Antimicrob Chemother (1980) 3.03
Genetic similarity and maintenance of Candida albicans strains from a group of AIDS patients, demonstrated by DNA fingerprinting. J Clin Microbiol (1992) 2.98
Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation. Emerg Infect Dis (1999) 2.96
Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol (2006) 2.86
Outbreak of systemic Candida albicans in intensive care unit caused by cross infection. Br Med J (Clin Res Ed) (1985) 2.74
Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. National Committee for Clinical Laboratory Standards. Antimicrob Agents Chemother (2001) 2.68
Modification and extension of tests for differentiation of Candida species and strains. Sabouraudia (1983) 2.68
ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect (2014) 2.47
Problems in the laboratory assessment of antifungal activity. Postgrad Med J (1979) 2.43
A triple deletion of the secreted aspartyl proteinase genes SAP4, SAP5, and SAP6 of Candida albicans causes attenuated virulence. Infect Immun (1997) 2.35
Analysis of Candida albicans phenotypes from different geographical and anatomical sources. J Clin Microbiol (1983) 2.33
Mechanisms and clinical impact of antifungal drug resistance. J Med Vet Mycol (1994) 2.32
Application of DNA typing methods to Candida albicans epidemiology and correlations with phenotype. Rev Infect Dis (1990) 2.30
Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro. Antimicrob Agents Chemother (1982) 2.28
Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transpl Infect Dis (1999) 2.28
Molecular biological characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother (1997) 2.27
Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus. Antimicrob Agents Chemother (2003) 2.27
Disruption of each of the secreted aspartyl proteinase genes SAP1, SAP2, and SAP3 of Candida albicans attenuates virulence. Infect Immun (1997) 2.24
Virulence for mice of a proteinase-secreting strain of Candida albicans and a proteinase-deficient mutant. J Gen Microbiol (1983) 2.18
Inducible proteinase of Candida albicans in diagnostic serology and in the pathogenesis of systemic candidosis. J Med Microbiol (1980) 2.17
Collaborative consensus for optimized multilocus sequence typing of Candida albicans. J Clin Microbiol (2003) 2.17
Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother (2001) 2.13
An examination of the production of hydrolytic enzymes and toxins by pathogenic strains of Candida albicans. J Gen Microbiol (1971) 2.10
Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species. Antimicrob Agents Chemother (1997) 2.09
Genital candidosis. Clin Exp Dermatol (1982) 2.00
Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother (1998) 2.00
Candida infections in AIDS patients. Int J STD AIDS (1992) 1.98
The activity in vitro and in vivo of a new imidazole antifungal, ketoconazole. J Antimicrob Chemother (1980) 1.75
ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect (2014) 1.70
Morphogenesis in Candida albicans. Crit Rev Microbiol (1985) 1.65
Multilocus sequence typing of the pathogenic fungus Aspergillus fumigatus. J Clin Microbiol (2007) 1.65
Sequence of the Candida albicans gene encoding the secretory aspartate proteinase. J Med Vet Mycol (1991) 1.61
Posaconazole salvage treatment in paediatric patients: a multicentre survey. Eur J Clin Microbiol Infect Dis (2010) 1.60
Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob Agents Chemother (1999) 1.60
Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob Agents Chemother (2011) 1.59
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect (2012) 1.55
Relative inhibition factors--a novel approach to the assessment of antifungal antibiotics in vitro. J Antimicrob Chemother (1984) 1.54
Initial experience in therapy for progressive mycoses with itraconazole, the first clinically studied triazole. Rev Infect Dis (1987) 1.53
Multicenter evaluation of broth microdilution method for susceptibility testing of Cryptococcus neoformans against fluconazole. J Clin Microbiol (1996) 1.51
Human beta-defensins: differential activity against candidal species and regulation by Candida albicans. J Dent Res (2005) 1.50
Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother (1991) 1.49
Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis (2001) 1.48
Improved method for estimation of azole antifungal inhibitory concentrations against Candida species, based on azole/antibiotic interactions. J Med Vet Mycol (1986) 1.48
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect (2012) 1.48
Relevance of antigenicity of Candida albicans growth phases to diagnosis of systemic candidiasis. Br Med J (1973) 1.47
Multisite reproducibility of the Etest MIC method for antifungal susceptibility testing of yeast isolates. J Clin Microbiol (1996) 1.45
Effectiveness of terbinafine in cutaneous alternariosis. Br J Dermatol (2000) 1.44
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect (2012) 1.41
A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother (1997) 1.41
Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole. J Clin Microbiol (2005) 1.41
Candida albicans strain types from the genitalia of patients with and without Candida infection. Eur J Obstet Gynecol Reprod Biol (1983) 1.40
Candida albicans proteinase as a virulence factor in the pathogenesis of Candida infections. Zentralbl Bakteriol Mikrobiol Hyg A (1985) 1.40
A morphology index for characterization of cell shape in Candida albicans. J Gen Microbiol (1989) 1.40
Correlative relationship between proteinase production, adherence and pathogenicity of various strains of Candida albicans. J Med Vet Mycol (1986) 1.38
Prevalence of pathogenic yeasts and humoral antibodies to candida in diabetic patients. J Clin Pathol (1978) 1.38
Molecular analysis of CaMnt1p, a mannosyl transferase important for adhesion and virulence of Candida albicans. Proc Natl Acad Sci U S A (1998) 1.36
ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. Clin Microbiol Infect (2014) 1.36
Biotyping of medically important fungi. Curr Top Med Mycol (1985) 1.35
Academic selection criteria and subsequent performance. Med Educ (1990) 1.30
Antifungal effects of fluconazole (UK 49858), a new triazole antifungal, in vitro. J Antimicrob Chemother (1986) 1.29
Origin of Cryptococcus neoformans var. neoformans diploid strains. J Clin Microbiol (2001) 1.28
Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J Clin Microbiol (2012) 1.27
The effect of growth medium of filament production in Candida albicans. Sabouraudia (1974) 1.27
Antifungal relative inhibition factors: BAY l-9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole and vibunazole (BAY n-7133) compared in vitro with nine established antifungal agents. J Antimicrob Chemother (1984) 1.26
Enzyme activities associated with carbohydrate synthesis and breakdown in the yeast and mycelial forms of Candida albicans. J Gen Microbiol (1973) 1.26
Epidemiology of vaginal Candida infection: significance of numbers of vaginal yeasts and their biotypes. Eur J Obstet Gynecol Reprod Biol (1987) 1.25
Optimum conditions for initiation of filamentation in Candida albicans. Can J Microbiol (1975) 1.22
Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect (2010) 1.21
Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother (2001) 1.20
Control of an outbreak of systemic Candida albicans. Br Med J (Clin Res Ed) (1985) 1.19
Prevalence of serotype D in Cryptococcus neoformans isolates from HIV positive and HIV negative patients in Italy. Mycoses (1997) 1.19
The Oral HIV/AIDS Research Alliance: updated case definitions of oral disease endpoints. J Oral Pathol Med (2009) 1.18
The epidemiologic patterns of drug-resistant Mycobacterium tuberculosis infections: a community-based study. Am Rev Respir Dis (1989) 1.17
Effects of imidazole- and triazole-derivative antifungal compounds on the growth and morphological development of Candida albicans hyphae. J Gen Microbiol (1985) 1.16
Molecular and genetic characterization of a serotype A MATa Cryptococcus neoformans isolate. Microbiology (2003) 1.16
Genetic polymorphism of Aspergillus fumigatus in clinical samples from patients with invasive aspergillosis: investigation using multiple typing methods. J Clin Microbiol (2001) 1.15
Binding of plasma proteins to Candida species in vitro. J Gen Microbiol (1988) 1.14
Susceptibility testing of pathogenic fungi with itraconazole: a process analysis of test variables. J Antimicrob Chemother (2001) 1.14
Histoplasmosis in Europe: report on an epidemiological survey from the European Confederation of Medical Mycology Working Group. Med Mycol (2008) 1.12
Identification of Candida glabrata by a 30-second trehalase test. J Clin Microbiol (2002) 1.11
Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds. J Clin Microbiol (2007) 1.11
Genotyping Cryptococcus neoformans var. neoformans with specific primers designed from PCR-fingerprinting bands sequenced using a modified PCR-based strategy. Med Mycol (2000) 1.10
Purified Candida albicans proteinase in the serological diagnosis of systemic candidosis. JAMA (1980) 1.09
Disseminated Candida infection syndrome in heroin addicts--dominance of a single Candida albicans biotype. J Med Microbiol (1987) 1.09
Isolation of Candida species on media with and without added fluconazole reveals high variability in relative growth susceptibility phenotypes. Antimicrob Agents Chemother (1997) 1.06
Infections due to Achromobacter xylosoxidans. Case report and review of the literature. Infection (1987) 1.06